Predictive Oncology (POAI) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 10, 2020
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		15,213,188
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and Cash Equivalents	$ 3,394,078	$ 150,831
Accounts Receivable	272,493	297,055
Inventories	235,368	190,156
Prepaid Expense and Other Assets	426,704	160,222
Total Current Assets	4,328,643	798,264
Fixed Assets, net	2,409,721	1,507,799
Total, Net Carrying Amount	3,539,597	3,649,412
Lease Right-of-Use Assets	1,528,150	729,745
Goodwill	15,690,290	15,690,290
Total Assets	27,496,401	22,375,510
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	2,449,046	3,155,641
Notes Payable – Net of Discounts of $282,099 and $350,426	4,412,377	4,795,800
Accrued Expenses	2,649,160	2,371,633
Derivative Liability	4,629,570	50,989
Deferred Revenue	38,582	40,384
Lease Liability	473,043	459,481
Total Current Liabilities	14,651,778	10,873,928
Lease Liability – Net of current portion	1,055,107	270,264
Other long-term liabilities	98,358
Total Liabilities	15,805,243	11,144,192
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 13,190,787 and 4,056,652 outstanding	131,908	40,567
Additional paid-in capital	102,163,864	93,653,667
Accumulated Deficit	(90,605,406)	(82,498,711)
Total Stockholders' Equity	11,691,158	11,231,318
Total Liabilities and Stockholders' Equity	27,496,401	22,375,510
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		35,000
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		$ 3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Discount of note payable	$ 282,099	$ 350,426
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	13,190,787	4,056,652
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,500,000	3,500,000
Preferred stock, shares outstanding (in shares)	0	3,500,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	350	350
Preferred stock, shares outstanding (in shares)	0	285

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue		$ 182,784	$ 286,151	$ 477,727	$ 541,392
Cost of goods sold		85,261	118,390	177,918	192,106
Gross margin		97,523	167,761	299,809	349,286
General and administrative expense		3,211,817	3,310,368	6,040,293	4,808,314
Operations expense		521,116	1,271,258	1,069,869	1,737,824
Sales and marketing expense		133,015	685,029	397,424	1,239,245
Total operating loss		(3,768,425)	(5,098,894)	(7,207,777)	(7,436,097)
Gain on revaluation of cash advances to Helomics			1,222,244		1,222,244
Other income		(52,965)	3,223	(52,968)	(50,209)
Other expense		(729,837)	(607,343)	(1,846,912)	(1,157,711)
Gain (loss) on derivative instruments		422,081	211,940	394,974	231,348
Gain on notes receivables associated with asset purchase		1,290,000		1,290,000
Loss on equity method investment					(439,637)
Gain on revaluation of equity method in investment			6,164,260		6,164,260
Net income (loss)		(3,577,378)	1,465,104	(8,106,695)	(1,828,080)
Deemed dividend on Series E Convertible Preferred Stock			20,398		20,398
Net income (loss) attributable to common shareholders per common shares-basic and diluted		$ (3,577,378)	$ 1,444,706	$ (8,106,695)	$ (1,848,478)
Gain (loss) per common share basic (in dollars per share)		$ (0.36)	$ 0.49	$ (1.10)	$ (0.81)
Gain (loss) per common share diluted (in dollars per share)		$ (0.36)	$ 0.24	$ (1.10)	$ (0.81)
Weighted average shared used in computation - basic (in shares)	[1]	9,838,152	2,960,937	7,362,240	2,274,754
Weighted average shared used in computation - diluted (in shares)		9,838,152	6,007,078	7,362,240	2,274,754
[1]	Includes 1,390,166 contingently issuable shares related to prefunded warrants when outstanding during the six months ended June 30, 2020 and 122,000 abeyance shares during the six months ended June 30, 2020.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders Equity (Unaudited) - USD ($)	Chief Executive Officer [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Common Stock [Member]	Chief Executive Officer [Member]Additional Paid-in Capital [Member]	Chief Executive Officer [Member]Retained Earnings [Member]	Chief Executive Officer [Member]	Private Placement [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]	May 2020 Offering [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	May 2020 Offering [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	May 2020 Offering [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	May 2020 Offering [Member]Common Stock [Member]	May 2020 Offering [Member]Additional Paid-in Capital [Member]	May 2020 Offering [Member]Retained Earnings [Member]	May 2020 Offering [Member]	Asset Purchase Agreement [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Asset Purchase Agreement [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Asset Purchase Agreement [Member]Common Stock [Member]	Asset Purchase Agreement [Member]Additional Paid-in Capital [Member]	Asset Purchase Agreement [Member]Retained Earnings [Member]	Asset Purchase Agreement [Member]	Bridge Notes [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Bridge Notes [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Bridge Notes [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Bridge Notes [Member]Common Stock [Member]	Bridge Notes [Member]Additional Paid-in Capital [Member]	Bridge Notes [Member]Retained Earnings [Member]	Bridge Notes [Member]	Warrants Issued to CEO [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Warrants Issued to CEO [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Warrants Issued to CEO [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Warrants Issued to CEO [Member]Common Stock [Member]	Warrants Issued to CEO [Member]Additional Paid-in Capital [Member]	Warrants Issued to CEO [Member]Retained Earnings [Member]	Warrants Issued to CEO [Member]	Warrants Held by Noteholders [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Warrants Held by Noteholders [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Warrants Held by Noteholders [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Warrants Held by Noteholders [Member]Common Stock [Member]	Warrants Held by Noteholders [Member]Additional Paid-in Capital [Member]	Warrants Held by Noteholders [Member]Retained Earnings [Member]	Warrants Held by Noteholders [Member]	Prefunded Warrant [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Prefunded Warrant [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Prefunded Warrant [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Prefunded Warrant [Member]Common Stock [Member]	Prefunded Warrant [Member]Additional Paid-in Capital [Member]	Prefunded Warrant [Member]Retained Earnings [Member]	Prefunded Warrant [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Common Stock [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]Retained Earnings [Member]	Conversion of Series E Preferred Stock to Common Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Common Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]Retained Earnings [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]	Asset Purchase Agreement [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Director [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Director [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Director [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Director [Member]Common Stock [Member]	Director [Member]Additional Paid-in Capital [Member]	Director [Member]Retained Earnings [Member]	Director [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018																																																																												79,246			1,409,175
Balance at Dec. 31, 2018																																																																												$ 792			$ 14,092	$ 63,146,533	$ (63,107,945)	$ 53,472
Shares issued pursuant to CEO exchange agreement			$ 78	$ 49,922		$ 50,000			$ 2,864	$ 2,426,845		$ 2,429,709
Shares issued pursuant to CEO exchange agreement (in shares)			7,813						286,375
Warrants issued pursuant to 2020 convertible debt																																					$ 318,058		$ 318,058
Shares issued pursuant to note conversions - bridge loan																													$ 160	$ 89,840		$ 90,000
Shares issued pursuant to note conversions - bridge loan (in shares)																													15,985
Vesting expense																																																																																263,600		263,600
Net loss																																																																																	(3,293,184)	(3,293,184)
Balance (in shares) at Mar. 31, 2019																																																																												79,246			1,736,015
Balance at Mar. 31, 2019																																																																												$ 792			$ 17,360	66,452,982	(66,401,129)	70,005
Shares issued in forbearance agreement																																																																															$ 166	158,183		158,349
Shares issued in forbearance agreement (in shares)																																																																															16,667
Balance (in shares) at Dec. 31, 2018																																																																												79,246			1,409,175
Balance at Dec. 31, 2018																																																																												$ 792			$ 14,092	63,146,533	(63,107,945)	53,472
Net loss																																																																																		(1,828,080)
Balance (in shares) at Jun. 30, 2019																																																																												79,246	3,500,000	84	3,097,476
Balance at Jun. 30, 2019																																																																												$ 792	$ 35,000	$ 1	$ 30,975	87,160,845	(64,936,025)	22,291,588
Balance (in shares) at Mar. 31, 2019																																																																												79,246			1,736,015
Balance at Mar. 31, 2019																																																																												$ 792			$ 17,360	66,452,982	(66,401,129)	70,005
Warrants issued pursuant to 2020 convertible debt																																					$ 23,550		$ 23,550					$ 117,241		$ 117,241																																		6,261,591		6,261,591
Shares issued pursuant to note conversions - bridge loan																													$ 399	148,173		148,572
Shares issued pursuant to note conversions - bridge loan (in shares)																													39,873
Vesting expense																																																																																1,380,620		1,380,620
Net loss																																																																																	1,465,104	1,465,104
Exercise of warrants and issuance of new warrant																																																																															$ 579	5,207		5,786
Exercise of warrants and issuance of new warrant (in shares)																																																																															57,856
Balance (in shares) at Jun. 30, 2019																																																																												79,246	3,500,000	84	3,097,476
Balance at Jun. 30, 2019																																																																												$ 792	$ 35,000	$ 1	$ 30,975	87,160,845	(64,936,025)	22,291,588
Stock issued to extinguish debt as part of Helomics purchase consideration																																																																															$ 8,637	6,454,672		6,463,309
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																																															863,732
Stock issued for Helomics acquisition (in shares)																																																																													3,500,000		400,000
Stock issued for Helomics acquisition																																																																													$ 35,000		$ 4,000	5,573,250		5,612,250
Issuance of Series E Preferred shares																																																																														$ 1		743,559		743,560
Issuance of Series E Preferred shares (in shares)																																																																														84
Balance (in shares) at Dec. 31, 2019																																																																												79,246	3,500,000	258	4,056,652
Balance at Dec. 31, 2019																																																																												$ 792	$ 35,000	$ 3	$ 40,567	93,653,667	(82,498,711)	11,231,318
Shares issued pursuant to CEO exchange agreement																																																																															$ 500	129,500		130,000
Shares issued pursuant to CEO exchange agreement (in shares)																																																																															50,000
Inducement shares issued pursuant to promissory note extension																																																																															$ 300	40,950		41,250
Inducement shares issued pursuant to promissory note extension (in shares)																																																																															30,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement																																																																															$ 2,600	455,223		457,823
Issuance of shares and prefunded warrants pursuant to March 2020 private placement (in shares)																																																																															260,000
Inducement shares issued pursuant to 2020 convertible debt and warrants																																																																															$ 468	119,532		120,000
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)																																																																															46,875
Warrants issued pursuant to 2020 convertible debt																																																																																116,951		116,951
Shares issued pursuant to note conversions - bridge loan																													$ 1,700	$ 265,628		$ 267,328																																														$ (1)	$ 1,412	(1,411)
Shares issued pursuant to note conversions - bridge loan (in shares)																													170,000																																																	(50)	141,191
Shares issued pursuant to Equity Line (in shares)																																																																															943,000
Shares issued pursuant to Equity Line																																																																															$ 9,430	1,860,469		1,869,899
Shares issued to consultant and other																																																																															$ 1,550	360,750		362,300
Shares issued to consultant and other (in shares)																																																																															155,000
Vesting expense																																																																																287,838		287,838
Net loss																																																																																	(4,529,317)	(4,529,317)
Balance (in shares) at Mar. 31, 2020																																																																												79,246	3,500,000	208	5,852,718
Balance at Mar. 31, 2020																																																																												$ 792	$ 35,000	$ 2	$ 58,527	97,289,097	(87,028,028)	10,355,390
Balance (in shares) at Dec. 31, 2019																																																																												79,246	3,500,000	258	4,056,652
Balance at Dec. 31, 2019																																																																												$ 792	$ 35,000	$ 3	$ 40,567	93,653,667	(82,498,711)	11,231,318
Net loss																																																																																		(8,106,695)
Balance (in shares) at Jun. 30, 2020																																																																												79,246			13,190,787
Balance at Jun. 30, 2020																																																																												$ 792			$ 131,908	102,163,864	(90,605,406)	11,691,158
Balance (in shares) at Mar. 31, 2020																																																																												79,246	3,500,000	208	5,852,718
Balance at Mar. 31, 2020																																																																												$ 792	$ 35,000	$ 2	$ 58,527	97,289,097	(87,028,028)	10,355,390
Shares issued pursuant to CEO exchange agreement																$ 13,968	$ 591,949		$ 605,917
Shares issued pursuant to CEO exchange agreement (in shares)																1,396,826
Issuance of shares and prefunded warrants pursuant to March 2020 private placement																																																		$ 13,902	$ (13,148)		$ 754
Warrants issued pursuant to 2020 convertible debt																																																																																62,373		62,373
Shares issued pursuant to note conversions - bridge loan																																																								$ (2)	$ 12,574	$ (12,572)				$ (35,000)		$ 3,500	$ 31,500
Shares issued pursuant to note conversions - bridge loan (in shares)																																																								(208)	1,257,416
Vesting expense																																																																																134,939		134,939
Net loss																																																																																	(3,577,378)	(3,577,378)
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement																																																																															$ 15,335	2,177,543		2,192,878
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)																																																		1,390,166																													1,533,481
Shares issued pursuant to series D preferred stock conversions (in shares)																																																														(3,500,000)		350,004
Shares issued in connection with Asset Purchase Agreement																						$ 1,150	$ 185,150		$ 186,300
Shares issued in connection with Asset Purchase Agreement (in shares)																						115,000
Exercise of warrants and issuance of new warrant																																																																															$ 12,748	1,682,237		1,694,985
Exercise of warrants and issuance of new warrant (in shares)																																																																															1,274,826
Director compensation																																																																								$ 204	$ 34,796		$ 35,000
Director compensation (in shares)																																																																								20,350
Balance (in shares) at Jun. 30, 2020																																																																												79,246			13,190,787
Balance at Jun. 30, 2020																																																																												$ 792			$ 131,908	$ 102,163,864	$ (90,605,406)	$ 11,691,158

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flow from operating activities:
Net loss	$ (8,106,695)	$ (1,828,080)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable		795,353
Accrued interest revenue		(42,746)
Loss on equity method investment		439,637
Gain on revaluation of equity method investment		(6,164,260)
Gain on note receivable in connection with asset purchase	(1,290,000)
Depreciation and amortization	402,738	259,362
Vesting expense	422,777	1,644,220
Equity instruments issued for management, consultant, and other	(397,300)
Amortization of debt discount	858,353	1,068,256
Loss on valuation of equity-linked instruments and derivative liability	394,974	231,348
Gain on revaluation of cash advances to Helomics		(1,222,244)
Debt extinguishment costs	300,000
Equity instruments issued in connection with 2020 convertible debt	20,695
Loss on fixed asset disposal	118,472
Changes in assets and liabilities:
Accounts receivable	113,769	141,325
Inventories	(45,212)	(55,665)
Prepaid expense and other assets	(197,182)	66,989
Accounts payable	(614,651)	718,483
Accrued expenses	505,380	(104,114)
Deferred revenue	(1,802)	6,641
Net cash used in operating activities	(6,721,084)	(4,045,495)
Cash flow from investing activities:
Advance on notes receivable		(975,000)
Cash received from notes receivable		154,418
Cash received in Helomics Acquisition		248,102
Proceeds from asset sales	133,850
Acquisition of intangibles	(43,874)	(8,433)
Net cash provided by (used in) investing activities:	89,976	(580,913)
Cash flow from financing activities:
Extinguishment of convertible debt		(220,241)
Proceeds from debt issuance	2,761,867	1,525,000
Proceeds from exercise of warrants into common stock	1,866,554	5,786
Proceeds from issuance of Series E convertible preferred stock		743,560
Repayment of debt	(1,459,973)
Payment penalties	(247,327)
Proceeds from issuance of common stock pursuant to equity line	1,869,899
Issuance of common stock, A, B and prefunded warrants, net	5,057,919	2,479,708
Other financing (security deposit)	25,416
Net cash provided by financing activities	9,874,355	4,533,813
Net increase (decrease) in cash and cash equivalents	3,243,247	(92,595)
Cash at beginning of period	150,831	162,152
Cash at end of period	3,394,078	69,557
Non-cash transactions:
Bridge loan conversion into common stock	$ 267,328	$ 238,573
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)	2,322,878
Inducement shares issued pursuant to convertible debt	$ 99,305
Inducement shares issued for debt extension	41,250
Warrants issued pursuant to debt issuance	179,324
Put and conversion derivative from debt issuance	141,463
Series D preferred stock conversions	35,000
Increase to operating lease right of use asset and lease liability due to lease modification	995,571
Asset purchase acquired for notes receivable and common stock	1,492,500
Forbearance settlement bridge loan		503,009
Additional warrants issued pursuant to CEO note payable		32,215
Consideration given for acquisition of Helomics		26,711,191
Series E Convertible Preferred Stock [Member]
Non-cash transactions:
Series E preferred stock conversions	$ 3

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company's wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company's segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $90,605,406. not 2019 first 2020, no may $3,394,078 June 30, 2020 $5,466,830 June 30, 2020, six may October 2019, $15,000,000 three no three first 2020, $9,874,355, not one not Coronavirus Outbreak In March 2020, 19 not 19 19 may not no 19 may Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company's position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2020. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements during the reporting period. Actual results could materially differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The Company had no June 30, 2020 December 31, 2019. Fair Value Measurements As outlined in ASC – 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company's investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 8 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not December 31, 2019 $770,250 no June 30, 2020. Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not Goodwill is not first not may first December 31, 2019 $8,100,000 Consistent with policy, as of June 30, 2020, $9,874,355 six June 30, 2020, June 30, 2020, not not Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses and to recognize shipping and handling costs at point of sale. The Company has elected a practical expedient and does not one Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company Sales Agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer's contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the domestic and international sales segments. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company's current product sales contracts do not Warranty The Company generally provides one no not Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company's ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient's tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient's tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company's performance obligations are satisfied at a point in time when test reports are delivered. For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease to the estimate of the transaction price, provided that such adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company's efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2020, December 31, 2019, $272,493 $297,055, The Company's deferred revenues related primarily to maintenance plans as of June 30, 2020 December 31, 2019 $38,582 $40,384, Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.62% - 1.78% 2.00% - 2.76% Expected life (yeas) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.33% - 0.79% 1.93% - 2.58% Expected life (years) 2 – 5.5 5 Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no During 2020 2019, 382 may may not 382 Tax years subsequent to 2016 Offering Costs Costs incurred which are direct and incremental to an offering of the Company's securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $2,818,144 Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Reclassifications Certain reclassifications have been made to the prior years' financial statements to conform to the current year presentation. The reclassifications had no Acquisition activities Acquisition of Quantitative Medicine On January 24, 2020, July 1, 2020. See Note 13 Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023. Newly formed subsidiaries The Company formed Extraordinary Vaccine Development Corporation as a wholly-owned subsidiary in May 2020. The Company also formed Soluble Biotech Inc. as a wholly-owned subsidiary in May 2020. May 2020. Note 7 Recent Developments On July 8, 2020, July 9, 2020, 2022 2020 April 2, 2020, The Company has evaluated all of its activities and concluded that no 13

Note 2 - Notes Receivable

Note 2 - Notes Receivable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 2 The Company had a secured promissory note receivable from CytoBioscience for $1,112,524 “2017 8% February 28, 2020. 2019, first April 2019. not first 2019. 2019, On May 27, 2020, two 125,000 may $1.29 2017 $1,290,000 $1,492,500.

Note 3 - Inventories

Note 3 - Inventories	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 3 Inventory balances are as follows: As of June 30, As of Finished goods $ 69,407 $ 91,410 Raw materials 154,794 69,821 Work-In-Process 11,167 28,925 Total $ 235,368 $ 190,156

Note 4 - Fixed Assets

Note 4 - Fixed Assets	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 The Company's fixed assets consist of the following: As of June 30, As of Computers and office equipment $ 391,464 $ 508,143 Leasehold improvements 188,014 188,014 Laboratory equipment 2,527,660 1,401,210 Manufacturing tooling 108,955 108,956 Demo equipment 73,051 73,051 Total 3,289,144 2,279,373 Less: Accumulated depreciation 879,423 771,574 Total Fixed Assets, Net $ 2,409,721 $ 1,507,799 Depreciation expense was $249,049 $153,302 six June 30, 2020 2019, $118,974 $131,420 three June 30, 2020 2019,

Note 5 - Intangible Assets

Note 5 - Intangible Assets	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 5 The components of intangible assets were as follows: As of June 30, 2020 As of December 31, 2019 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents &Trademarks $ 382,897 $ (202,758 ) $ 180,139 $ 339,023 $ (195,286 ) $ 143,737 Developed Technology 2,882,000 (180,125 ) 2,701,875 2,882,000 (108,075 ) 2,773,925 Customer Relationships 445,000 (185,417 ) 259,583 445,000 (111,250 ) 333,750 Tradename 398,000 - 398,000 398,000 - 398,000 Total $ 4,107,897 $ (568,300 ) $ 3,539,597 $ 4,064,023 $ (414,611 ) $ 3,649,412 Amortization expense was $153,689 $106,060 six June 20, 2020 2019, $77,184 $88,416 three June 20, 2020 2019, The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2020: Year ending December 31, Expense 2020 $ 154,101 2021 308,201 2022 196,951 2023 159,868 2024 159,868 Thereafter 2,162,608 Total $ 3,141,597

Note 6 - Notes Payable

Note 6 - Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 6 The balances of notes payable were as follows: Due Date As of As of Bridge loan September 30, 2020 $ 1,721,776 $ 1,989,104 Promissory note 2019 September 30, 2020 980,833 680,833 Promissory note 2020 T1 September 30, 2020 490,000 - Promissory note 2020 T2 September 30, 2020 480,000 - Promissory note 2020 T3 September 30, 2020 480,000 - Paycheck Protection Plan April 20, 2022 541,867 Short term borrowing May 26, 2020 - 18,563 Short term borrowing June 10, 2020 - 147,783 Short term borrowing June 20, 2020 - 194,943 Dr. Schwartz notes September 30, 2020 - 2,115,000 Total Notes Payable, gross 4,694,476 5,146,226 Less: Unamortized discount 282,099 350,426 Total Notes Payable, net $ 4,412,377 $ 4,795,800 Bridge Loan In September 2018, two $2,297,727 $2,000,000. 65,000 107,178 $11.55 8% February 2019, $344,659 16,667 September 2019, one March 19, 2020, June 28, 2020. July 15, 2020 July 2020 September 30, 2020. Note 13 No three six June 30, 2020 $430,444 not June 30, 2020. June 30, 2020 $1,721,776, $52,909. Each investor received the right to convert all or any part of its bridge loan into shares of the Company's common stock at a conversion factor that is the lesser of a discounted 20 may 1 2 267,833 June 30, 2020, no six June 30, 2020 2019, $267,328 $238,573 170,000 55,859 Dr. Schwartz Notes In November 2018, $370,000. December 31, 2018, one $370,000 $63,028. November 30, 2018 July 15, 2019, $1,920,000 two 22,129 $8.36 February 1, 2019 first October 2019, not During January 2020, two $2,115,000 12% September 30, 2020 50,000 no December 31, 2019. Effective as of April 21, 2020, January 31, 2020 $2,115,000. twelve 12% September 30, 2020. April 21, 2020 $77,878, $2,192,878 1,533,481 $1.43 April 21, 2020. 1 not 766,740 three 2 not 766,741 six Promissory Note 2019 During September 2019, $847,500 $700,000. 8,857 68,237 $6.21 sixth fifth 8% On March 19, 2020, March 27, 2020 March 31, 2020 June 27, 2020. $300,000 30,000 10% 470, Debt first 2020, $300,000 July 15, 2020 July 2020 September 30, 2020. Note 13 No three six June 30, 2020 $196,167 not June 30, 2020. June 30, 2020, $980,833 zero Promissory Note 2020 On February 5, 2020, $1,450,000 $1,200,000. three $400,000 third February 5, 2020, March 5, 2020, April 5, 2020, 8% $2.589. No three six June 30, 2020 $290,000 not June 30, 2020. June 30, 2020, $1,450,000 $229,190. July 2020 September 30, 2020. Note 13 As additional consideration, the Company issued to the investor warrants to purchase 94,631, 92,700 92,700 second third sixth $2.992 46,875 first Short Term Borrowings The Company entered into short-term borrowings with an investor. The maturity date of the notes is six 8% three six June 30, 2020, $1,098,684 $1,020,000 $1,459,973 $247,327 six June 30, 2020. no June 30, 2020. April 2020 On April 20, 2020, $541,867 2 1% 6 60 Pursuant to the terms of the PPP, the promissory note, or a portion thereof, may no may

Note 7 - Stockholders' Equity,

Note 7 - Stockholders' Equity, Stock Options and Warrants	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 Series D Preferred Stock In April 2019, 3,500,000 10:1 1 50% 2 one April 4, 2020, 3,500,000 350,004 Series E Convertible Preferred Stock In June September 2019, 258 0.056857% six June 13, 2019. 12 $289,935, December 13, 2019. In May 2020, June 13, 2020 207.7 0.056857% 207.7 June 13, 2020 1,257,416 11.8% June 12, 2020. Equity Line On October 24, 2019, $15,000,000 three 104,651 $450,000 three may six June 30, 2020, 943,000 $1,869,899 June 30, 2020, $12,810,907 March 2020 On March 18, 2020, 260,000 $2.121 1,390,166 $2.12 $0.001 1,650,166 $1.88 five one 1,650,166 $1.88 two In addition, and in lieu of common shares, the investors also purchased prefunded warrants to purchase 1,390,166 $2.12 $0.0001 second 2020. The sale of the offering shares, prefunded warrants and A and B warrants resulted in gross proceeds of $3,498,612 $3,127,818 March 18, 2020, Note 8 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Schwartz Note Exchange Effective as of April 21, 2020, January 31, 2020 $2,115,000. 1,533,481 $1.43 See Note 6 May 2020 During May 2020, 1,396,826 $0.01 1,396,826 $1.575 $1.45 five one $2,200,001 $1,930,101 May 8, 2020. Acquisition from Soluble Therapeutics and BioDtech On May 27, 2020, two 125,000 may 25,000 six 25,000 nine one may 10,000 six $1,492,500. June 2020 During June 2020, 1,396,826 May 2020 $1.45 $0.125 100% five one $1.80. $2,130,701 $1,865,800 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 76,862 1.93 7,992,706 1.54 Forfeited (25,169 ) 7.58 (119,441 ) 6.47 Exercised - - (2,786,992 ) 0.79 Outstanding at June 30, 2020 818,117 $ 10.54 7,257,883 $ 5.83 Stock-based compensation expense recognized for three June 30, 2020 June 30, 2019 $134,939 $1,380,620, six June 30, 2020 June 30, 2019 $422,777 $1,644,220, $59,210 18

Note 8 - Derivatives

Note 8 - Derivatives	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 8 Management concluded the September 2018 20 six June 30, 2020, $50,989 $211,939 three June 30, 2020 June 30, 2019, $50,989 $231,347 six June 30, 2020 June 30, 2019, zero June 30, 2020 $50,989 December 31, 2019. On May 21, 2019, February 1, 2019 first 5,753 2019. $22,644 zero December 31, 2019, January 2020, Management concluded the Promissory Note 2020 815, Derivatives and Hedging two $68,796, $52,125 $20,542 second third three June 30, 2020, June 30, 2020, $7,628, $8,907 $12,210 second third Management concluded the A, B and agent warrants issued in connection with the March 2020 $2,669,995. June 30, 2020, $2,830,744 $51,026 $160,749 three six June 30, 2020, Management concluded the warrants and agent warrants issued in connection with the May 2020 $1,324,184. June 2020, $460,065 three six June 30, 2020. June 30, 2020, $108,527 $26,033 three six June 30, 2020. In connection with the June 2020 June 2020 $1,749,721. June 30, 2020, $1,555,653 June 30, 2020, $105,901 $82,322 three six June 30, 2020 $5,845 three six June 30, 2020. The table below discloses changes in value of the Company's embedded derivative liabilities related to the bridge loan and the derivative included in the note payable agreements with Dr. Schwartz. Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Loss recognized to revalue derivative instrument at fair value 422,081 Derivative liability balance at June 30, 2020 $ 4,629,570

Note 9 - Loss Per Share

Note 9 - Loss Per Share	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 9 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended Six Months Ended 2020 2019 2020 2019 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (3,577,378 ) $ 1,444,706 $ (8,106,695 ) $ (1,848,478 ) Denominator: Weighted average common shares outstanding-basic (1) 9,838,152 2,960,937 7,362,240 2,274,754 Effect of diluted stock options, warrants, and preferred stock (2) 3,046,141 Weighted average common shares outstanding - diluted 9,838,152 6,007,078 7,362,240 2,274,754 Gain (loss) per common share-basic $ (0.36 ) $ 0.49 $ (1.10 ) $ (0.81 ) Gain (loss) per common share- diluted $ (0.36 ) $ 0.24 $ (1.10 ) $ (0.81 ) ( 1 Includes 1,390,166 six June 30, 2020 122,000 six June 30, 2020. ( 2 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six months ended 2020 2019 Options 818,117 729,975 Warrants 7,257,883 2,025,971 Convertible debt 574,367 130,307 Preferred stock: series B 79,246 79,246 Preferred stock: series D - 350,004 Preferred stock: series E - 1,484,634

Note 10- Segments

Note 10- Segments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 10 The Company has determined its operating segments in accordance with ASC 280 Segment Reporting The Company has three 1 three six June 30, 2020 Revenue Three Months Ended June 30, Six Months Ended 2020 2019 2020 2019 Domestic $ 173,738 $ 259,082 $ 453,551 $ 478,743 International - 1,464 - 37,044 Helomics 9,046 25,605 24,176 25,605 Corporate - - - - Total $ 182,784 $ 286,151 $ 477,727 $ 541,392 Segment Gain (Loss) Three Months Ended Six Months Ended 2020 2019 2020 2019 Domestic $ (524,744 ) $ (917,754 ) $ (865,524 ) $ (1,859,477 ) International (47,923 ) (97,552 ) (116,988 ) (196,213 ) Helomics (1,795,312 ) (1,663,937 ) (3,207,777 ) (1,663,937 ) Corporate (1,209,399 ) 4,144,347 (3,916,406 ) 1,891,547 Total $ (3,577,378 ) $ 1,465,104 $ (8,106,695 ) $ (1,828,080 ) Assets As of As of 2020 2019 Domestic $ 770,156 $ 670,841 International 279,627 298,952 Helomics 22,270,730 21,275,306 Corporate 4,175,888 130,411 Total $ 27,496,401 $ 22,375,510

Note 11 - Leases

Note 11 - Leases	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 11 On May 1, 2020, 91 43 rd October 27, 2017. February 28, 2021 two one 91 43 rd no

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 12 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company's directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women's cancer. There has been no Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, $12,000 six May 1, 2019, one three $13,500 Dr. Carl Schwartz, the Company's CEO, made loans to the Company in exchange for promissory notes and common stock. See Note 6

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 Acquisition of Quantitative Medicine On July 1, 2020, 954,719 $1,750,000. 477,359 207,144 six one may Amendments to and Extensions of Promissory Notes July 15, 2020, $4,152,609, September 30, 2020. July 15, 2020, August 5, 2020, September 5, 2020 October 5, 2020. $345,000, $1,280,833 $172,500, $1,622,500.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company's wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company's segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $90,605,406. not 2019 first 2020, no may $3,394,078 June 30, 2020 $5,466,830 June 30, 2020, six may October 2019, $15,000,000 three no three first 2020, $9,874,355, not one not
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak In March 2020, 19 not 19 19 may not no 19 may
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company's position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2020. may not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements during the reporting period. Actual results could materially differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The Company had no June 30, 2020 December 31, 2019.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in ASC – 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company's investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 8
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not December 31, 2019 $770,250 no June 30, 2020.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not Goodwill is not first not may first December 31, 2019 $8,100,000 Consistent with policy, as of June 30, 2020, $9,874,355 six June 30, 2020, June 30, 2020, not not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company's sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses and to recognize shipping and handling costs at point of sale. The Company has elected a practical expedient and does not one Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company Sales Agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer's contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the domestic and international sales segments. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company's current product sales contracts do not Warranty The Company generally provides one no not Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company's ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient's tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient's tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company's performance obligations are satisfied at a point in time when test reports are delivered. For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease to the estimate of the transaction price, provided that such adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company's efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2020, December 31, 2019, $272,493 $297,055, The Company's deferred revenues related primarily to maintenance plans as of June 30, 2020 December 31, 2019 $38,582 $40,384,
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.62% - 1.78% 2.00% - 2.76% Expected life (yeas) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.33% - 0.79% 1.93% - 2.58% Expected life (years) 2 – 5.5 5
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no During 2020 2019, 382 may may not 382 Tax years subsequent to 2016
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company's securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $2,818,144
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior years' financial statements to conform to the current year presentation. The reclassifications had no
Business Combinations Policy [Policy Text Block]	Acquisition activities Acquisition of Quantitative Medicine On January 24, 2020, July 1, 2020. See Note 13
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.
Newly Formed Subsidiaries, Policy [Policy Text Block]	Newly formed subsidiaries The Company formed Extraordinary Vaccine Development Corporation as a wholly-owned subsidiary in May 2020. The Company also formed Soluble Biotech Inc. as a wholly-owned subsidiary in May 2020. May 2020. Note 7
Recent Developments, Policy [Policy Text Block]	Recent Developments On July 8, 2020, July 9, 2020, 2022 2020 April 2, 2020, The Company has evaluated all of its activities and concluded that no 13

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 6 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Six Months Ended June 30, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.62% - 1.78% 2.00% - 2.76% Expected life (yeas) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% - 86.8% 78.6% - 79.8% Risk-free interest rate 0.33% - 0.79% 1.93% - 2.58% Expected life (years) 2 – 5.5 5

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of June 30, As of Finished goods $ 69,407 $ 91,410 Raw materials 154,794 69,821 Work-In-Process 11,167 28,925 Total $ 235,368 $ 190,156

Note 4 - Fixed Assets (Tables)

Note 4 - Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of June 30, As of Computers and office equipment $ 391,464 $ 508,143 Leasehold improvements 188,014 188,014 Laboratory equipment 2,527,660 1,401,210 Manufacturing tooling 108,955 108,956 Demo equipment 73,051 73,051 Total 3,289,144 2,279,373 Less: Accumulated depreciation 879,423 771,574 Total Fixed Assets, Net $ 2,409,721 $ 1,507,799

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of June 30, 2020 As of December 31, 2019 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents &Trademarks $ 382,897 $ (202,758 ) $ 180,139 $ 339,023 $ (195,286 ) $ 143,737 Developed Technology 2,882,000 (180,125 ) 2,701,875 2,882,000 (108,075 ) 2,773,925 Customer Relationships 445,000 (185,417 ) 259,583 445,000 (111,250 ) 333,750 Tradename 398,000 - 398,000 398,000 - 398,000 Total $ 4,107,897 $ (568,300 ) $ 3,539,597 $ 4,064,023 $ (414,611 ) $ 3,649,412
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2020 $ 154,101 2021 308,201 2022 196,951 2023 159,868 2024 159,868 Thereafter 2,162,608 Total $ 3,141,597

Note 6 - Notes Payable (Tables)

Note 6 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date As of As of Bridge loan September 30, 2020 $ 1,721,776 $ 1,989,104 Promissory note 2019 September 30, 2020 980,833 680,833 Promissory note 2020 T1 September 30, 2020 490,000 - Promissory note 2020 T2 September 30, 2020 480,000 - Promissory note 2020 T3 September 30, 2020 480,000 - Paycheck Protection Plan April 20, 2022 541,867 Short term borrowing May 26, 2020 - 18,563 Short term borrowing June 10, 2020 - 147,783 Short term borrowing June 20, 2020 - 194,943 Dr. Schwartz notes September 30, 2020 - 2,115,000 Total Notes Payable, gross 4,694,476 5,146,226 Less: Unamortized discount 282,099 350,426 Total Notes Payable, net $ 4,412,377 $ 4,795,800

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity, Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 76,862 1.93 7,992,706 1.54 Forfeited (25,169 ) 7.58 (119,441 ) 6.47 Exercised - - (2,786,992 ) 0.79 Outstanding at June 30, 2020 818,117 $ 10.54 7,257,883 $ 5.83

Note 8 - Derivatives (Tables)

Note 8 - Derivatives (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Loss recognized to revalue derivative instrument at fair value 422,081 Derivative liability balance at June 30, 2020 $ 4,629,570

Note 9 - Loss Per Share (Tables

Note 9 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended 2020 2019 2020 2019 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (3,577,378 ) $ 1,444,706 $ (8,106,695 ) $ (1,848,478 ) Denominator: Weighted average common shares outstanding-basic (1) 9,838,152 2,960,937 7,362,240 2,274,754 Effect of diluted stock options, warrants, and preferred stock (2) 3,046,141 Weighted average common shares outstanding - diluted 9,838,152 6,007,078 7,362,240 2,274,754 Gain (loss) per common share-basic $ (0.36 ) $ 0.49 $ (1.10 ) $ (0.81 ) Gain (loss) per common share- diluted $ (0.36 ) $ 0.24 $ (1.10 ) $ (0.81 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six months ended 2020 2019 Options 818,117 729,975 Warrants 7,257,883 2,025,971 Convertible debt 574,367 130,307 Preferred stock: series B 79,246 79,246 Preferred stock: series D - 350,004 Preferred stock: series E - 1,484,634

Note 10- Segments (Tables)

Note 10- Segments (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, Six Months Ended 2020 2019 2020 2019 Domestic $ 173,738 $ 259,082 $ 453,551 $ 478,743 International - 1,464 - 37,044 Helomics 9,046 25,605 24,176 25,605 Corporate - - - - Total $ 182,784 $ 286,151 $ 477,727 $ 541,392 Three Months Ended Six Months Ended 2020 2019 2020 2019 Domestic $ (524,744 ) $ (917,754 ) $ (865,524 ) $ (1,859,477 ) International (47,923 ) (97,552 ) (116,988 ) (196,213 ) Helomics (1,795,312 ) (1,663,937 ) (3,207,777 ) (1,663,937 ) Corporate (1,209,399 ) 4,144,347 (3,916,406 ) 1,891,547 Total $ (3,577,378 ) $ 1,465,104 $ (8,106,695 ) $ (1,828,080 ) As of As of 2020 2019 Domestic $ 770,156 $ 670,841 International 279,627 298,952 Helomics 22,270,730 21,275,306 Corporate 4,175,888 130,411 Total $ 27,496,401 $ 22,375,510

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Oct. 28, 2019	Oct. 24, 2019USD ($)	Oct. 31, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Apr. 04, 2019	Mar. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance				$ (90,605,406)		$ (82,498,711)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				3,394,078		150,831
Long-term Debt, Current Maturities, Total				5,466,830
Proceeds from Debt and Equity Financing, Net				9,874,355
Cash Equivalents, at Carrying Value, Total				0		0
Goodwill, Impairment Loss				0		8,100,000
Net Cash Provided by (Used in) Financing Activities, Total				9,874,355	$ 4,533,813
Accounts Receivable, after Allowance for Credit Loss, Total				272,493		297,055
Contract with Customer, Liability, Total				38,582		40,384
Income Tax Expense (Benefit), Total				0
Unrecognized Tax Benefits, Ending Balance				0
Liability for Uncertainty in Income Taxes, Current				$ 0
Open Tax Year				2016 2017 2018 2019 2020
Cash, Uninsured Amount				$ 2,818,144
Licensing Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total				$ 0		$ 770,250
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised			$ 15,000,000
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage								25.00%
Business Acquisition, Percentage of Voting Interests Acquired							75.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	6 Months Ended
	Jun. 30, 2020
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years	[1]
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	6 years
[1]	Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Expected dividend yield	0.00%	0.00%
Expected life (yeas) (Year)	10 years	10 years
Minimum [Member]
Expected stock price volatility	82.60%	78.60%
Risk-free interest rate	0.62%	2.00%
Maximum [Member]
Expected stock price volatility	86.80%	79.80%
Risk-free interest rate	1.78%	2.76%
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input	0.826	0.786
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input	0.868	0.798
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input	0.0033	0.0193
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input	0.0079	0.0258
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input		5
Measurement Input, Expected Term [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input	2
Measurement Input, Expected Term [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input	5.5

Note 2 - Notes Receivable (Deta

Note 2 - Notes Receivable (Details Textual) - USD ($)	May 27, 2020	May 26, 2020	Jun. 30, 2020
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total	$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	125,000
Other Nonoperating Income	$ 1,290,000
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total			$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage			8.00%
InventaBioTech [Member] | Promissory Note 2017 [Member]
Nonmonetary Transaction, Gain (Loss) Recognized on Transfer		$ 1,290,000

Note 3 - Inventories - Schedule

Note 3 - Inventories - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Finished goods	$ 69,407	$ 91,410
Raw materials	154,794	69,821
Work-In-Process	11,167	28,925
Total	$ 235,368	$ 190,156

Note 4 - Fixed Assets (Details

Note 4 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Depreciation, Total	$ 118,974	$ 131,420	$ 249,049	$ 153,302

Note 4 - Fixed Assets - Schedul

Note 4 - Fixed Assets - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant, and Equipment Gross	$ 3,289,144	$ 2,279,373
Property, Plant, and Equipment Gross	3,289,144	2,279,373
Less: Accumulated depreciation	879,423	771,574
Total Fixed Assets, Net	2,409,721	1,507,799
Office Equipment [Member]
Property, Plant, and Equipment Gross	391,464	508,143
Property, Plant, and Equipment Gross	391,464	508,143
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	188,014
Property, Plant, and Equipment Gross	188,014	188,014
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	2,527,660	1,401,210
Property, Plant, and Equipment Gross	2,527,660	1,401,210
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,956
Property, Plant, and Equipment Gross	108,955	108,956
Demo Equipment [Member]
Property, Plant, and Equipment Gross	73,051	73,051
Property, Plant, and Equipment Gross	$ 73,051	$ 73,051

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Amortization of Intangible Assets, Total	$ 77,184	$ 88,416	$ 153,689	$ 106,060

Note 5 - Intangible Assets - Co

Note 5 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accumulated Amortization	$ (568,300)	$ (414,611)
Net Carrying Amount	3,141,597
Total, Gross Carrying Costs	4,107,897	4,064,023
Total, Net Carrying Amount	3,539,597	3,649,412
Trade Names [Member]
Tradename	398,000	398,000
Patents and Trademarks [Member]
Gross Carrying Costs	382,897	339,023
Accumulated Amortization	(202,758)	(195,286)
Net Carrying Amount	180,139	143,737
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000	2,882,000
Accumulated Amortization	(180,125)	(108,075)
Net Carrying Amount	2,701,875	2,773,925
Customer Relationships [Member]
Gross Carrying Costs	445,000	445,000
Accumulated Amortization	(185,417)	(111,250)
Net Carrying Amount	$ 259,583	$ 333,750

Note 5 - Intangible Assets - Es

Note 5 - Intangible Assets - Estimated Future Amortization Expense (Details)	Jun. 30, 2020USD ($)
2020	$ 154,101
2021	308,201
2022	196,951
2023	159,868
2024	159,868
Thereafter	2,162,608
Total	$ 3,141,597

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual)	Apr. 21, 2020USD ($)$ / sharesshares	Apr. 20, 2020USD ($)	Mar. 19, 2020USD ($)shares	Feb. 05, 2020USD ($)$ / sharesshares	Sep. 28, 2018USD ($)$ / sharesshares	Jan. 31, 2020USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Feb. 27, 2019USD ($)shares	Nov. 30, 2018USD ($)	Apr. 05, 2020USD ($)shares	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Jul. 15, 2019USD ($)$ / sharesshares	Mar. 05, 2020shares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Debt Instrument, Face Amount											$ 4,694,476		$ 4,694,476				$ 5,146,226
Debt Instrument, Unamortized Discount, Total											282,099		282,099				350,426
Gain (Loss) on Extinguishment of Debt, Total													(300,000)
Payments for Penalties													$ 247,327
Dr. Schwartz [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 1.43
Stock Issued, Agreement, Not to be Transferred or Sold For Three Months (in shares) | shares	766,740
Stock Issued, Agreement, Not to be Transferred or Sold for Six Months (in shares) | shares	766,741
Investor of Promissory Note [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				46,875
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares						50,000
Proceeds from Related Party Debt									$ 370,000						$ 1,920,000
Conversion of Bridge Loan to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares													170,000	55,859
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 1.43
Conversion of Promissory Note Into Common Stock [Member] | Dr. Schwartz [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	1,533,481
Bridge Loan Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					107,178
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 11.55
Dr. Schwartz Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares															22,129
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 8.36
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares							68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 6.21
Warrants Issued With Promissory Note, One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				94,631
Warrants Issued With Promissory Note, Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares																92,700
Warrants Issued With Promissory Note, Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares										92,700
Warrants Issued With Promissory Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 2.992
Convertible Promissory Note [Member]
Debt Instrument, Face Amount											1,721,776		$ 1,721,776				1,989,104
Dr. Schwartz Note, One [Member]
Debt Instrument, Face Amount																		$ 370,000
Debt Instrument, Unamortized Discount, Total																		$ 63,028
DrSchwartz Notes [Member]
Debt Instrument, Face Amount	$ 2,115,000					$ 2,115,000											2,115,000
Debt Instrument, Interest Rate, Stated Percentage						12.00%
Short-term Debt, Total	2,192,878					$ 2,115,000
Interest Payable	$ 77,878
DrSchwartz Notes [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	1,533,481
Second Promissory Note [Member]
Debt Instrument, Face Amount				$ 1,450,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Proceeds from Short-term Debt, Total				$ 400,000						$ 1,200,000
Payments for Penalties											0		0
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 2.589
Borrowings Against Equity Line [Member]
Debt Instrument, Face Amount											$ 1,098,684		$ 1,098,684
Debt Instrument, Interest Rate, Stated Percentage											8.00%		8.00%
Proceeds from Short-term Debt, Total													$ 1,020,000
Payments for Penalties													247,327
Repayments of Short-term Debt, Total													1,459,973
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount					$ 2,297,727
Proceeds from Notes Payable, Total					$ 2,000,000
Stock Issued During Period, Shares, New Issues (in shares) | shares					65,000			16,667
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Increase (Decrease), Net, Total								$ 344,659
Penalties Accrued											$ 430,444		430,444
Bridge Loan											1,721,776		1,721,776
Debt Instrument, Unamortized Discount, Total											52,909		52,909
Debt Instrument, Convertible, Threshold Trading Days					20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares (in shares) | shares					267,833
Debt Conversion, Original Debt, Amount													267,328	$ 238,573
Securities Purchase Agreements [Member] | Promissory Note [Member]
Debt Instrument, Face Amount			$ 300,000				$ 847,500
Stock Issued During Period, Shares, New Issues (in shares) | shares							8,857
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Penalties Accrued											196,167		196,167
Debt Instrument, Unamortized Discount, Total											229,190		229,190
Short-term Debt, Total											980,833		980,833
Proceeds from Short-term Debt, Total							$ 700,000
Stock Issued During Period, Shares, Extension of Notes Payable (in shares) | shares			30,000
Gain (Loss) on Extinguishment of Debt, Total												$ 300,000
Payments for Penalties												$ 0
Securities Purchase Agreements [Member] | Second Promissory Note [Member]
Penalties Accrued											290,000		290,000
Short-term Debt, Total											1,450,000		1,450,000
Paycheck Protection Program CARES Act [Member]
Debt Instrument, Face Amount											$ 541,867		$ 541,867
Proceeds from Issuance of Long-term Debt, Total		$ 541,867

Note 6 - Notes Payable - Notes

Note 6 - Notes Payable - Notes Payable (Details) - USD ($)	Jun. 30, 2020	Apr. 21, 2020	Jan. 31, 2020	Dec. 31, 2019
Notes Payable, Gross	$ 4,694,476			$ 5,146,226
Debt Instrument, Unamortized Discount, Total	282,099			350,426
Notes Payable	4,412,377			4,795,800
Paycheck Protection Program CARES Act [Member]
Notes Payable, Gross	541,867
Convertible Promissory Note [Member]
Notes Payable, Gross	1,721,776			1,989,104
Promissory Note, One [Member]
Notes Payable, Gross	980,833			680,833
Promissory Note, Two [Member]
Notes Payable, Gross	490,000
Promissory Note, Three [Member]
Notes Payable, Gross	480,000
Promissory Note, Four [Member]
Notes Payable, Gross	480,000
Borrowings Against Equity Line, One [Member]
Notes Payable, Gross				18,563
Borrowings Against Equity Line, Two [Member]
Notes Payable, Gross				147,783
Borrowings Against Equity Line, Three [Member]
Notes Payable, Gross				194,943
DrSchwartz Notes [Member]
Notes Payable, Gross		$ 2,115,000	$ 2,115,000	$ 2,115,000

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Jun. 12, 2020shares	May 27, 2020USD ($)shares	May 08, 2020USD ($)$ / sharesshares	Apr. 21, 2020USD ($)$ / sharesshares	Apr. 04, 2020shares	Mar. 18, 2020$ / sharesshares	Oct. 24, 2019USD ($)shares	Jun. 30, 2020USD ($)$ / sharesshares	May 31, 2020shares	Mar. 18, 2020USD ($)$ / sharesshares	Apr. 30, 2019shares	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)shares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Jan. 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / sharesshares
Stock Issued During Period, Value, New Issues | $													$ 130,000
Debt Instrument, Face Amount | $								$ 4,694,476				$ 4,694,476					$ 4,694,476			$ 5,146,226
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.01				$ 0.01					$ 0.01			$ 0.01
Share-based Payment Arrangement, Expense | $												$ 134,939		$ 1,380,620			$ 422,777	$ 1,644,220
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $														$ 59,210				$ 59,210
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)																	1 year 180 days
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total | $		$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		125,000
Asset Purchase Shares Issued Shares Escrow Deposit To Be Released Upon Six Months Anniversary Of Closing (in shares)		(25,000)
Asset Purchase Shares Issued, Shares Escrow Deposit To Be Released Upon Nine Months Anniversary Of Closing (in shares)		25,000
Business Acquisition, Right to Reclaim, Number of Shares (in shares)		10,000
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 1.43
DrSchwartz Notes [Member]
Debt Instrument, Face Amount | $				$ 2,115,000															$ 2,115,000	$ 2,115,000
DrSchwartz Notes [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,533,481
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																	10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																	3 years
Warrants issued with Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,396,826			1,390,166				1,390,166
Price of Warrant (in dollars per share) | $ / shares						$ 2.12
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.45			$ 0.001				$ 0.001
Warrants and Rights Outstanding, Term (Year)			5 years 182 days
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 1.575
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,650,166				1,650,166
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.88				$ 1.88
Warrants and Rights Outstanding, Term (Year)						5 years 182 days				5 years 182 days
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,650,166				1,650,166
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.88				$ 1.88
Warrants and Rights Outstanding, Term (Year)						2 years				2 years
Prefunded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,390,166				1,390,166
Price of Warrant (in dollars per share) | $ / shares										$ 2.12
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.0001				$ 0.0001
Warrant Issued in Connection With May 2020 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.45				$ 1.45					$ 1.45
Class of Warrant or Right Issued During Period (in shares)								1,396,826
June 2020 Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.80				$ 1.80					$ 1.80
Warrants and Rights Outstanding, Term (Year)								5 years 182 days				5 years 182 days					5 years 182 days
Class Of Warrant Or Right, Purchase Price Per Warrant (in dollars per share) | $ / shares								$ 0.125				$ 0.125					$ 0.125
Class of Warrant or Right, Percentage of Shares Issued Pursuant to Exercise of Existing Warrant								100.00%				100.00%					100.00%
Proceeds from Issuance and Exercise of Warrants | $								$ 2,130,701
Proceeds from Issuance and Exercise of Warrants, Net | $								1,865,800
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised | $							$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)							104,651										943,000
Stock Issued During Period, Value, New Issues | $							$ 450,000										$ 1,869,899
Sale of Stock, Remaining Available Balance | $								$ 12,810,907				$ 12,810,907					$ 12,810,907
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,396,826							260,000
Stock Issued During Period, Value, New Issues | $															$ 2,429,709
Sale of Stock, Price Per Share (in dollars per share) | $ / shares						$ 2.121				$ 2.121
Proceeds from Issuance or Sale of Equity, Total | $										$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $										$ 3,127,818
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.01
Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $			$ 2,200,001
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $			$ 1,930,101
Conversion from Series D Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					3,500,000
Conversion of Stock, Shares Issued (in shares)					350,004
Conversion from Series E Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)									207.7
Conversion of Stock, Shares Issued (in shares)	1,257,416
Conversion of Stock, Shares Issued, Percentage of Outstanding Shares	11.80%								0.05686%
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	207.7
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)											3,500,000
Convertible Preferred Stock, Conversion Rate											10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate																0.00056857
Stock Issued During Period, Shares, Convertible Preferred Shares Issued (in shares)																258
Preferred Stock, Beneficial Conversion Feature | $																$ 289,935
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0				0					0			285

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Warrant [Member]
Number of Shares Outstanding (in shares)	2,171,610	362,664
Average Exercise Price Outstanding (in dollars per share)	$ 15.26	$ 41.67
Number of Shares Issued (in shares)	7,992,706	1,869,299
Average Exercise Price Issued (in dollars per share)	$ 1.54	$ 9.25
Number of Shares Forfeited (in shares)	(119,441)	(653)
Average Exercise Price Forfeited (in dollars per share)	$ 6.47	$ 3,249.28
Number of Shares Exercised (in shares)	(2,786,992)	(59,700)
Average Exercise Price Exercised (in dollars per share)	$ 0.79	$ 0.10
Number of Shares Outstanding (in shares)	7,257,883	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 5.83	$ 15.26
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	766,424	366,928
Average Exercise Price Outstanding (in dollars per share)	$ 11.34	$ 17.03
Number of Shares Issued (in shares)	76,862	423,295
Average Exercise Price Issued (in dollars per share)	$ 1.93	$ 6.53
Number of Shares Forfeited (in shares)	(25,169)	(23,799)
Average Exercise Price Forfeited (in dollars per share)	$ 7.58	$ 13.30
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	818,117	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 10.54	$ 11.34

Note 8 - Derivatives (Details T

Note 8 - Derivatives (Details Textual)	Sep. 28, 2018	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	May 08, 2020USD ($)	Mar. 31, 2020USD ($)	Mar. 18, 2020USD ($)	Feb. 05, 2020USD ($)	Dec. 31, 2019USD ($)	May 21, 2019shares	Dec. 31, 2018USD ($)
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total		$ 50,989	$ (211,939)	$ 50,989	$ (231,347)
Embedded Derivative, Fair Value of Embedded Derivative Liability		4,629,570		4,629,570			$ 2,814,798			$ 50,989
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		(422,081)	$ (211,940)	(394,974)	$ (231,348)
Chief Executive Officer [Member] | Warrants Issued for 2019 Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares											5,753
Bridge Loan Warrants [Member]
Derivative Liability, Total										50,989
Dr. Schwartz Notes Warrants [Member]
Derivative Liability, Total										$ 0		$ 22,644
Promissory Note 2020 Conversion Feature, Tranche One [Member]
Derivative Liability, Total		7,628		7,628
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 68,796
Promissory Note 2020 Conversion Feature, Tranche Two [Member]
Derivative Liability, Total		8,907		8,907
Embedded Derivative, Fair Value of Embedded Derivative Liability									52,125
Promissory Note 2020 Conversion Feature, Tranche Three [Member]
Derivative Liability, Total		12,210		12,210
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 20,542
A, B and Agent Warrants [Member]
Derivative Liability, Total		2,830,744		2,830,744				$ 2,669,995
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		51,026		160,749
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative Liability, Total						$ 1,324,184
Embedded Derivative, Fair Value of Embedded Derivative Liability		1,324,184		1,324,184
Warrant Issued in Connection With May 2020 Offering [Member]
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		(460,065)		(460,065)
Agent Warrants Issued In connection With May 2020 Offering [Member]
Derivative Liability, Total		108,527		108,527
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		(26,033)		(26,033)
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total		1,749,721		1,749,721
Embedded Derivative, Fair Value of Embedded Derivative Liability		1,749,721		1,749,721
Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total		1,555,653		1,555,653
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		82,322		82,322
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total		105,901		105,901
Gain (Loss) on Derivative Instruments, Net, Pretax, Total		$ 5,845		$ 5,845
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Convertible, Threshold Trading Days	20

Note 8 - Derivaitves - Change i

Note 8 - Derivaitves - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Derivative liability balance	$ 4,629,570	$ 2,814,798	$ 50,989
Gain recognized to revalue derivative instrument at fair value	(422,081)	(27,107)
Reclassification of Warrant liabilities to Equity on exercise	(1,701,756)
Loss recognized to revalue derivative instrument at fair value	422,081	27,107
A, B and Agent Warrants [Member]
Derivative instrument recognized		2,669,995
Promissory Note 2020 [Member]
Derivative instrument recognized	20,542	$ 120,921
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative liability balance	1,324,184
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative liability balance	$ 1,749,721

Note 9 - Loss Per Share (Detail

Note 9 - Loss Per Share (Details Textual)	6 Months Ended
	Jun. 30, 2020shares
Weighted Average Number of Shares, Abeyance Shares (in shares)	122,000
Prefunded Warrant [Member]
Weighted Average Number of Shares, Contingently Issuable (in shares)	1,390,166

Note 9 - Loss Per Share - Share

Note 9 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (3,577,378)	$ 1,444,706	$ (8,106,695)	$ (1,848,478)
Weighted average shared used in computation - basic (in shares)	[1]	9,838,152	2,960,937	7,362,240	2,274,754
Effect of diluted stock options, warrants and preferred stock (in shares)	[2]		3,046,141
Weighted average shared used in computation - diluted (in shares)		9,838,152	6,007,078	7,362,240	2,274,754
Gain (loss) per common share basic (in dollars per share)		$ (0.36)	$ 0.49	$ (1.10)	$ (0.81)
Gain (loss) per common share diluted (in dollars per share)		$ (0.36)	$ 0.24	$ (1.10)	$ (0.81)
[1]	Includes 1,390,166 contingently issuable shares related to prefunded warrants when outstanding during the six months ended June 30, 2020 and 122,000 abeyance shares during the six months ended June 30, 2020.
[2]	(2) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six months ended June 30, 2020 2019 Options 818,117 729,975 Warrants 7,257,883 2,025,971 Convertible debt 574,367 130,307 Preferred stock: series B 79,246 79,246 Preferred stock: series D - 350,004 Preferred stock: series E - 1,484,634

Note 9 - Loss Per Share - Antid

Note 9 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	818,117	729,975
Warrant [Member]
Antidilutive Securities (in shares)	7,257,883	2,025,971
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	574,367	130,307
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)		350,004
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)		1,484,634

Note 10- Segments (Details Text

Note 10- Segments (Details Textual)	6 Months Ended
	Jun. 30, 2020
Number of Operating Segments	3

Note 10 - Segments - Segments (

Note 10 - Segments - Segments (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Revenue	$ 182,784		$ 286,151		$ 477,727	$ 541,392
Net loss	(3,577,378)	$ (4,529,317)	1,465,104	$ (3,293,184)	(8,106,695)	(1,828,080)
Assets	27,496,401				27,496,401		$ 22,375,510
Corporate, Non-Segment [Member]
Revenue
Net loss	(1,209,399)		4,144,347		(3,916,406)	1,891,547
Assets	4,175,888				4,175,888		130,411
Domestic [Member] | Operating Segments [Member]
Revenue	173,738		259,082		453,551	478,743
Net loss	(524,744)		(917,754)		(865,524)	(1,859,477)
Assets	770,156				770,156		670,841
International [Member] | Operating Segments [Member]
Revenue			1,464			37,044
Net loss	(47,923)		(97,552)		(116,988)	(196,213)
Assets	279,627				279,627		298,952
Helomics Segment [Member] | Operating Segments [Member]
Revenue	9,046		25,605		24,176	25,605
Net loss	(1,795,312)		$ (1,663,937)		(3,207,777)	$ (1,663,937)
Assets	$ 22,270,730				$ 22,270,730		$ 21,275,306

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Jul. 15, 2020	Jul. 01, 2020	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument, Face Amount			$ 4,694,476	$ 5,146,226
Subsequent Event [Member] | Promissory Note [Member]
Debt Instrument, Face Amount	$ 4,152,609
Subsequent Event [Member] | Promissory Note [Member] | First Oasis Note [Member]
Debt Instrument, Increase (Decrease), Net, Total	345,000
Short-term Debt, Total	1,280,833
Subsequent Event [Member] | Promissory Note [Member] | Second Oasis Note [Member]
Debt Instrument, Increase (Decrease), Net, Total	172,500
Short-term Debt, Total	$ 1,622,500
Subsequent Event [Member] | Asset Purchase Agreement With Quantitative Medicine [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 1,750,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow (in shares)		477,359
Subsequent Event [Member] | Asset Purchase Agreement With Quantitative Medicine [Member] | Carnegie Mellon University [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		207,144
Subsequent Event [Member] | Other Capitalized Property Plant and Equipment [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		954,719